Zota Health Care Ltd Q1 FY27 Earnings Analysis

- Growth remains robust driven by both same-store growth (SSG) and new store additions. - Even without new store openings, a 25%-30% growth is achievable via mature and 1–2 year old stores. - New stores (~800 opened in FY26) are expected to deliver close to 100% growth in their second year. - FY27 plans include opening approximately 500–700 stores (80%-90% COCO format), moderating the pace in Q2 and Q3 but ramping up again in Q3 and Q4. - Revenue for FY27 could potentially approach INR 900+ crores, subject to execution on store additions and store-level performance. - Long-term vision includes scaling to 5,000+ Davaindia stores by FY29, supporting ongoing revenue traction. - Store maturation typically occurs over 3–5 years with mature stores achieving monthly sales of INR 6–7 lakhs.

- The company experienced strong revenue growth of 83.86% YoY in FY26, driven by rapid expansion of Davaindia stores and robust same-store sales growth (SSG). - Positive EBITDA of INR 2,597 lakhs achieved in FY26 with 4.82% margin, marking a turnaround from negative EBITDA in FY25. - Sustained same-store sales growth of 25%-30% expected even without new store additions, supported by strong growth in mature and newer stores. - Gross margins improving steadily, nearing peak levels but with some scope for further expansion due to private label model and scale benefits. - Store addition planned between 500-700 in FY27, balancing moderate expansion with focus on improving store-level profitability and operational efficiency. - COCO stores gross margins are over 70% and are sustainable with continued improvement expected. - Overall, growth trajectory remains robust; with scale benefits and margin expansion, earnings, operating profits, and EPS are expected to improve meaningfully in coming years.

- FY26 capex was around INR 114 crores, primarily in anticipation of upcoming store openings (Page 16). - Increase in inventory and capex aligns with planned store expansion (Page 16). - For FY27, the company plans to open 500-700 new stores, requiring continued capital investment (Page 6, Page 16). - Investments include intangible assets under development (~INR 14 crores) related to store pre-operative expenses like drug licenses and regulatory approvals (Page 11). - Focus remains on building a strong, scalable foundation to support the expanding store network (Page 18). - No specific mention of strategic investments beyond store expansion and brand endorsement investments.

- The transcript does not mention any current or planned fundraising through debt or equity. - The company completed a significant QIP (Qualified Institutional Placement) worth INR 350 crores previously to strengthen the balance sheet and support expansion. - No specific statements regarding new or future fundraising activities through debt or equity are provided in the transcript. - The focus appears to be on scaling operations, improving store-level profitability, and moderate store expansion without indicating additional capital raises. - Management highlights confidence in growth using existing capital and operational efficiencies rather than announcing fresh fundraising plans.

The transcript does not explicitly mention specific figures or details regarding the current or expected order book or pending orders for Zota Healthcare Limited. However, related insights include: - Around 400–600 stores were in the pipeline last quarter. - Approximately 230–240 stores were opened in the previous quarter. - The company expects to open roughly 200+ stores in the current quarter. - For FY27, they plan to open between 500 to 700 stores overall. - Store additions are primarily COCO format (80–90%), with 100–150 FOFO format stores. - Future expansion is calibrated to focus on improving profitability despite moderate store addition pace in some quarters. - Inventory and capex increases are largely in anticipation of upcoming store openings. No direct order book or order backlog figures are stated in the provided content.